SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5506 participants.
Also called NCT04418479
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 5,506 participants
- Sponsor
- Joo-Yong Hahn
- Registry
-
NCT04418479
-
- Other papers using this trial's data
- Clopidogrel vs Aspirin According to Diabetes Mellitus: A Prespecified Analysis of the SMART-CHOICE 3 Trial
- Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04418479. Randomized; no masking; primary purpose treatment. Start 2020-08-10 (actual); primary completion 2024-10-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3
- Acronym
- SMART-CHOICE3
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Joo-Yong Hahn
Record details
- Record id
cardio:ct-nct04418479- Content hash
0a9e5e9dbd31fb65b5d4bfe1ac6cc2c2394804629584d2cc4c7c85eefbbe7268